SLR Investment (SLRC) Q2 FY26 earnings call: guidance and Q&A

SLRC is maintaining a defensive investment approach, prioritizing asset-heavy, liquid collateral-backed lending over cash flow dependent structures. This strategy is a direct response to rising interest rates and eroding interest coverage for companies with flat or declining cash flows. The company views its specialty finance platform as a key differentiator, enabling it to navigate a challenging direct lending environment with less competition compared to the sponsor cash flow market. Nearly all Q2 originations were in specialty finance, a trend expected to continue.

The company has formed an AI committee to assess the risk of AI disruption on both potential new and existing investments. Historically, SLRC has avoided software lending due to concerns about the long-term durability of software IP. This decision is proving beneficial as the company's exposure to the software industry now stands at less than 1% of fair value. Management is positioning to be opportunistic as the $224 billion software maturity wall approaches, which KBRA estimates represents 22% of total private debt exposure.

At quarter end, the comprehensive portfolio totaled $3.2 billion, with an average exposure of $3.7 million. Approximately 98% of the portfolio consisted of senior secured loans, with 96% invested in first lien loans. Over 86% of the comprehensive portfolio is comprised of specialty finance investments. Despite two loans being placed on nonaccrual, the weighted average investment risk rating was under 2 (on a 1-4 scale), with 97.5% of the portfolio rated 2 or higher, indicating strong credit quality.

SLRC is actively expanding its ABL footprint through new hires, acquisitions, and sourcing partnerships. A new sourcing arrangement with a large U.S. commercial bank broadens origination reach, and the company is evaluating tuck-in acquisitions to fill regional and industry white space. Increased activity is observed from PE firms using ABL structures for LBOs, strategic acquisitions, and turnarounds, particularly in healthcare accounts receivable, where SLRC has specialized expertise.

The life science industry and corresponding capital markets are recovering, with the biotech index up 100% from its trough a year ago and 25% year-to-date. M&A activity has more than doubled, and FDA approvals are up 44% year-over-year. SLRC has expanded its life science finance team and product offerings, now issuing term sheets that combine traditional first lien term loans with asset-based revolvers for working capital needs, expecting portfolio growth in coming quarters.

SLRC maintains investment-grade ratings from Fitch, Moody's, and DBRS, with over 40% of its debt capital comprised of unsecured debt. The net debt-to-equity ratio stands at 1.16x, within the target range of 0.9x to 1.25x. The company increased its revolving facility capacity by $25 million, bringing total commitments to $995 million, and has over $900 million of available capital to deploy, positioning it to capitalize on market opportunities.